|
|
| | TGR5 (C-Term) Polyclonal Antibody Basic information |
| | TGR5 (C-Term) Polyclonal Antibody Chemical Properties |
| | TGR5 (C-Term) Polyclonal Antibody Usage And Synthesis |
| Description | TGR5, also known as GPBAR1, is a G protein-coupled receptor (GPCR) belonging to the bile acid receptor subclass. It is a plasma membrane-bound transmembrane protein and is primarily expressed in spleen and placenta. TGR5 is activated by the endogenous bile acids cholic acid , lithocholic acid , taurolithocholic acid , deoxycholic acid (Item Nos. 20756 | 18231), and chenodeoxycholic acid , among others. Activation of TGR5 by the synthetic agonist INT-777 decreases plasma triglyceride levels and urinary levels of albumin, thiobarbituric acid reactive substances (TBARS), and hydrogen peroxide, as well as prevents diabetic nephropathy, in a db/db mouse model of diabetes. Activation of TGR5 by INT-777 also prevents hepatic steatosis and increases in fat, liver, and brown adipose tissue mass in a mouse model of diet-induced obesity. Transgenic overexpression of TGR5 increases glucose tolerance, as well as plasma levels of insulin and glucagon-like peptide 1 (GLP-1), during an oral glucose tolerance test in mice fed a high-fat diet. Increased expression of TGR5 has been found in tissue samples from patients with intestinal-type adenocarcinoma or intestinal metaplasia, but not healthy mucosa. TGR5 protein levels are also increased in patient-derived Barrett''s esophagous and esophageal adenocarcinoma tissues. Cayman''s TGR5 (C-Term) Polyclonal Antibody can be used for Western blot and immunohistochemistry (IHC) applications. The antibody recognizes the C-terminal region of TGR5 from human samples. | | References | [1] ATUL TIWARI Pranab M. TGR5: an emerging bile acid G-protein-coupled receptor target for the potential treatment of metabolic disorders.[J]. Drug Discovery Today, 2009, 14 9-10: 523-530. DOI: 10.1016/j.drudis.2009.02.005
[2] XIAOXIN X WANG. G Protein-Coupled Bile Acid Receptor TGR5 Activation Inhibits Kidney Disease in Obesity and Diabetes.[J]. Journal of The American Society of Nephrology, 2016: 1362-1378. DOI: 10.1681/asn.2014121271
[3] ANA M P MELO Miguel T Tiago M Bandeiras. New insights into type II NAD(P)H:quinone oxidoreductases.[J]. Microbiology and Molecular Biology Reviews, 2004, 68 4: 603-616. DOI: 10.1128/mmbr.68.4.603-616.2004
[4] WEIBIAO CAO. Expression of bile acid receptor TGR5 in gastric adenocarcinoma.[J]. American journal of physiology. Gastrointestinal and liver physiology, 2013, 304 4: G322-7. DOI: 10.1152/ajpgi.00263.2012
[5] JIE HONG. Role of a novel bile acid receptor TGR5 in the development of oesophageal adenocarcinoma.[J]. Gut, 2010, 59 2: 170-180. DOI: 10.1136/gut.2009.188375 |
| | TGR5 (C-Term) Polyclonal Antibody Preparation Products And Raw materials |
|